Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iodine 131-labeled COL-1
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
iodine 131-labeled COL-1 is a radiolabeled monoclonal antibody therapy composed of the murine monoclonal antibody COL-1 conjugated with radioactive iodine isotope Iodine-131. The antibody (COL-1) specifically targets carcinoembryonic antigen (CEA), which is overexpressed in many gastrointestinal malignancies. Upon administration, the radiolabeled antibody binds to CEA-expressing tumor cells and delivers targeted beta radiation from Iodine-131, resulting in localized cytotoxicity and tumor cell death. This approach combines immunotargeting with radiotherapy for selective destruction of cancer cells while sparing most normal tissues. It has been evaluated primarily in patients with advanced gastrointestinal cancers such as colon, pancreatic, and gastric cancers[5].
- Other names
- COL-1 (when referring to the antibody component)131I-labeled COL-1
Beyond the preview
Go deeper on iodine 131-labeled COL-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iodine 131-labeled COL-1.